Isoxanthohumol reduces neointimal hyperplasia through the apelin/AKT pathway

Area of Science:

• Vascular Biology
• Pharmacology
• Cellular Signaling

Background:

• Vascular smooth muscle cell (VSMC) dysfunction drives neointimal hyperplasia and restenosis.
• Platelet-derived growth factor (PDGF)-BB and tumor necrosis factor-alpha (TNF-α) promote VSMC transformation and inflammation.
• Isoxanthohumol (IXN) exhibits anti-inflammatory, antiproliferative, and antimigratory properties.

Purpose of the Study:

• To investigate the therapeutic potential of Isoxanthohumol (IXN) in neointimal hyperplasia.
• To elucidate the molecular mechanisms underlying IXN's effects on VSMCs.

Main Methods:

• In vitro studies using PDGF-BB and TNF-α to induce VSMC abnormalities.
• Assessment of IXN's impact on VSMC proliferation, migration, and inflammation.
• In vivo evaluation of IXN in a rat femoral artery denudation model.
• Analysis of signaling pathways including apelin/AKT and AKT.

Main Results:

• IXN significantly inhibited PDGF-BB- and TNF-α-induced VSMC proliferation, migration, and inflammation.
• IXN modulated the apelin/AKT pathway in response to PDGF-BB and the AKT pathway in response to TNF-α.
• IXN treatment markedly reduced neointimal hyperplasia in a femoral artery injury model.

Conclusions:

• Isoxanthohumol (IXN) demonstrates significant therapeutic efficacy against neointimal hyperplasia.
• IXN acts by modulating critical signaling pathways involved in VSMC pathobiology.
• IXN represents a promising novel therapeutic agent for restenosis treatment.